Cell Salvage in Obstetrics: What the UK Data Actually Says About Safety

By Hayden Dando, Managing Director, Australian Blood Management

A question I’ve been asked more than almost any other over two decades in this profession:

Is cell salvage safe in obstetrics?

It’s a fair question. For a long time, the answer from mainstream obstetric practice was effectively “probably not”. Cell salvage was seen as standard in orthopaedic, spinal, cardiac and vascular surgery, but obstetric cases sat in their own category. The fear was amniotic fluid embolism — the rare, catastrophic clinical syndrome that has worried obstetricians and anaesthetists for a century.

That fear was understandable. It has also outlived the evidence.

The historical concern

Amniotic fluid embolism (AFE) is uncommon but severe. Incidence sits somewhere between 1 and 6 cases per 100,000 pregnancies depending on the series, with historical mortality rates reported as high as 60 to 80%, though contemporary series suggest lower figures with better supportive care. Pathophysiologically, it is now understood less as a mechanical embolism of amniotic debris and more as an anaphylactoid-type inflammatory response to fetal antigens entering the maternal circulation. The exact mechanism is still debated.

The connection to cell salvage is intuitive. If amniotic fluid and fetal debris can trigger AFE when they enter the maternal bloodstream during delivery, then surely sucking up the contents of a caesarean operative field, washing it, and returning it to the mother is asking for trouble.

That reasoning kept cell salvage out of obstetric theatres for a long time. The problem is that it was built on first principles rather than on evidence about what modern cell salvage actually removes.

The safety architecture of modern obstetric cell salvage

Contemporary obstetric cell salvage protocols are built around three safety layers, and each one matters.

Dual-suction technique. The initial suction — the one used before the baby is delivered and while amniotic fluid is visibly pooling in the operative field — is kept completely separate from the cell salvage collection. Only once the baby is out and the bulk of amniotic fluid has been cleared does the salvage suction come into play.

Leucocyte-depletion filtration (LDF). On transfusion, the salvaged red cell product is passed through a leucocyte-depletion filter. LDFs are designed to remove white cells from blood products, but they also substantially remove fetal squamous cells, trophoblastic material, lamellar bodies and other amniotic fluid components. Laboratory work over the past two decades has demonstrated that salvaged and LDF-filtered blood from obstetric cases has a contaminant profile comparable to maternal venous blood.

Washing. The wash cycle itself removes plasma, free haemoglobin, activated clotting factors, and small particulate matter. What is returned is concentrated, washed red cells.

None of these layers is perfect on its own. Together, they make the reinfused product clinically very different from the unfiltered operative field that the old AFE concern was built around.

What the SALVO trial showed

The definitive UK work on this is the SALVO trial — cell SALvage in Obstetrics — led by Khalid Khan and colleagues at Queen Mary University of London. The main clinical paper was published in PLoS Medicine in December 2017 (DOI: 10.1371/journal.pmed.1002471), with a full Health Technology Assessment monograph in early 2018 (DOI: 10.3310/hta22020). According to PubMed, SALVO remains the largest randomised controlled trial of intraoperative cell salvage during caesarean section ever conducted.

The scale matters. SALVO randomised 3,028 women across 26 UK obstetric units between June 2013 and April 2016. Women were stratified by emergency versus elective caesarean and assigned either to routine cell salvage or to standard care without it. The primary outcome was donor (allogeneic) blood transfusion. Secondary outcomes included fetomaternal haemorrhage, haemoglobin changes, length of stay, and — critically for this discussion — adverse events.

The headline numbers are worth reading precisely. Donor blood transfusion was needed in 2.5% of the cell salvage group and 3.5% of the control group, a reduction that narrowly missed conventional statistical significance (adjusted OR 0.65, 95% CI 0.42 to 1.01, p = 0.056). In the pre-planned emergency caesarean subgroup the reduction was statistically significant: 3.0% versus 4.6% (adjusted OR 0.58, 95% CI 0.34 to 0.99). In elective caesareans the effect was smaller and not significant.

So what did SALVO actually prove about effectiveness? It proved that cell salvage works where we would expect it to work most, in emergency caesareans with real blood loss. In planned elective cases where bleeding is usually modest, the statistical gain is smaller because the event rate is lower to begin with.

But the number I want to highlight for anyone still worried about safety is this. Across 3,028 women:

No case of amniotic fluid embolism was observed. Not one.

That is not conclusive proof that cell salvage can never contribute to AFE. AFE is too rare for even a 3,000-patient trial to rule out a small signal with complete certainty — but it is the strongest real-world safety signal the intervention has ever generated. And it is consistent with a now-large international literature spanning thousands of obstetric cell salvage cases.

For clinicians who grew up being told cell salvage was dangerous in obstetric practice, that reality is worth sitting with.

The FMH finding, and why it matters

SALVO did identify one genuine safety consideration, and it deserves attention rather than dismissal.

Fetomaternal haemorrhage (FMH), the passage of fetal red cells into the maternal circulation was more common in the cell salvage group among RhD-negative mothers with RhD-positive babies (25.6% versus 10.5%, adjusted OR 5.63, 95% CI 1.43 to 22.14, p = 0.013). This is not a catastrophic finding, but it has a real clinical consequence: adequate anti-D prophylaxis is essential. The Kleihauer–Betke test should be performed and the anti-D dose adjusted accordingly.

I think this is one of those findings where the trial did its job properly. It didn’t just tell us the intervention works. It identified the one specific risk that needs to be managed, and the management pathway — anti-D prophylaxis guided by Kleihauer-Betke — is already embedded in obstetric practice. We just need to make sure it happens.

Where the UK guidance landed

After SALVO, UK guidance moved. NICE guidance, the Obstetric Anaesthetists’ Association and AAGBI joint guidelines, and the Royal College of Obstetricians and Gynaecologists’ Green-top Guidelines on placenta praevia and placenta accreta spectrum disorders all now recommend consideration of cell salvage in caesareans where significant haemorrhage is anticipated or identified.

This is not a fringe intervention in UK obstetric practice anymore. It’s mainstream.

Where Australia sits

In Australia the picture is more uneven. The National Blood Authority’s Patient Blood Management Guidelines: Module 5 — Obstetrics and Maternity identifies cell salvage as appropriate for women at high risk of significant haemorrhage, particularly where donor blood may be unacceptable or unavailable. The NSQHS Blood Management Standard expects hospitals to have protocols in place for PBM interventions, including autotransfusion where clinically indicated.

But knowing something is recommended and having the service actually running on a Sunday night when a placenta accreta goes south are two different things. At many Australian maternity units cell salvage is theoretically available. At others it is not. Where it does exist, it often depends on one or two trained staff being reachable.

This is where specialist providers come in. At ABM we have been delivering obstetric cell salvage across New South Wales since 2006. We have specialists trained in the obstetric protocols, we stock the dedicated consumables and LDF filters, and we attend cases on standby for high-risk pregnancies. That model takes the question of “does our hospital do this” and replaces it with “can we get a team here”. For the maternity units we already work with, the answer is consistently yes.

A safety-first summary

If you take one thing away from this piece, let it be this. The evidence base for cell salvage in obstetrics is now strong enough that the historical safety concerns should no longer drive clinical decisions. The largest and highest-quality UK trial — the SALVO trial — showed no amniotic fluid embolism across thousands of women. The intervention reduces donor blood exposure, particularly in emergency caesareans. The one genuine risk — increased fetomaternal haemorrhage in RhD-negative women with RhD-positive babies — is manageable with the standard anti-D protocols that are already embedded in obstetric practice.

The remaining questions are operational rather than clinical. Is the service available when you need it? Are the staff trained? Are the protocols current? Are the consumables on the shelf?

If your maternity unit does not have clear, confident answers to those questions, it is a conversation worth having. We are happy to be part of it.

References and further reading

•          Khan KS, Moore PAS, Wilson MJ, et al. Cell salvage and donor blood transfusion during cesarean section: A pragmatic, multicentre randomised controlled trial (SALVO). PLoS Medicine 2017;14(12):e1002471. DOI: 10.1371/journal.pmed.1002471

•          Khan KS, Moore P, Wilson M, et al. A randomised controlled trial and economic evaluation of intraoperative cell salvage during caesarean section in women at risk of haemorrhage: the SALVO trial. Health Technol Assess2018;22(2):1–88. DOI: 10.3310/hta22020

•          McLoughlin C, Roberts TE, Jackson LJ, et al. Cost-effectiveness of cell salvage and donor blood transfusion during caesarean section: results from a randomised controlled trial. BMJ Open 2019;9(2):e022352. DOI: 10.1136/bmjopen-2018-022352

•          Dhariwal SK, Khan KS, Allard S, Wilson M, Moore P. Does current evidence support the use of intraoperative cell salvage in reducing the need for blood transfusion in caesarean section? Current Opinion in Obstetrics & Gynecology 2014;26(6):425–430. DOI: 10.1097/GCO.0000000000000116

•          National Blood Authority Australia. Patient Blood Management Guidelines: Module 5 — Obstetrics and Maternity.

Bibliographic citations retrieved from PubMed.

Hayden Dando is the Managing Director of Australian Blood Management (ABM), which has provided specialist perfusion, cell salvage, and blood management services since 2006. If you would like to discuss expanding obstetric cell salvage at your hospital, https://www.australianbloodmanagement.com.au/make-a-booking